BioNTech Is No Longer a Buy, Says Analyst
Despite some good news recently about the coronavirus vaccine it co-developed, BioNTech (NASDAQ: BNTX) has been hit with a recommendation downgrade.
In a research note published on Tuesday, Bryan Garnier analyst Olga Smolentseva changed her view on the stock to neutral from the previous buy recommendation. At the same time, though, she significantly raised her price target on the stock, from $135 per share to $206.
Image source: Getty Images.
Source Fool.com
